CRISPR/Cpf1 Gene Editing Systems Using Recombinant AsCpf1 and LbCpf1 crRNA
Summary
The USPTO published patent application US20260098249A1 for Integrated DNA Technologies covering recombinant AsCpf1 and LbCpf1 nucleic acids and polypeptides for CRISPR/Cpf1 endonuclease gene editing systems in mammalian cell lines. The application includes ribonucleoprotein complexes using length-truncated, chemically-modified, or dual-modified AsCpf1 crRNAs and methods for performing gene editing using these systems.
What changed
The USPTO published patent application US20260098249A1 assigned to Integrated DNA Technologies, Inc. covering recombinant AsCpf1 and LbCpf1 nucleic acids and polypeptides for use in CRISPR/Cpf1 endonuclease systems, ribonucleoprotein complexes, and gene editing methods in mammalian cell lines. The application claims systems using AsCpf1 crRNA variants including length-truncated crRNAs, chemically-modified crRNAs, and crRNAs with both modifications.
Affected parties including biotechnology companies, drug manufacturers, and research institutions developing CRISPR-based gene editing applications should monitor this patent's prosecution for potential licensing implications or freedom-to-operate considerations. The patent, if granted, would cover specific crRNA modifications and recombinant Cpf1 systems for mammalian cell gene editing.
What to do next
- Monitor patent prosecution for grant or rejection
- Review claims for freedom-to-operate analysis
Archived snapshot
Apr 12, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
CRISPR/CPF1 Systems and Methods
Application US20260098249A1 Kind: A1 Apr 09, 2026
Assignee
Integrated DNA Technologies, Inc.
Inventors
Mark Aaron BEHLKE, Michael Allen COLLINGWOOD, Rolf TURK, Christopher Anthony VAKULSKAS
Abstract
This invention pertains to recombinant AsCpf1 and LbCpf1 nucleic acids and polypeptides for use in CRISPR/Cpf1 endonuclease systems and mammalian cell lines encoding recombinant AsCpf1 or LbCpf1 polypeptides. The invention includes recombinant ribonucleoprotein complexes and CRSPR/Cpf1 endonuclease systems having a suitable AsCpf1 crRNA is selected from a length-truncated AsCpf1 crRNA, a chemically-modified AsCpf1 crRNA, or an AsCpf1 crRNA comprising both length truncations and chemical modifications. Methods of performing gene editing using these systems and reagents are also provided.
CPC Classifications
C12N 9/22 C12N 15/102 C12N 15/111 C12N 15/113 C12N 15/63 C12N 15/8509 C12N 15/90 C12N 2310/20 C12Y 301/30
Filing Date
2025-12-08
Application No.
19412076
Named provisions
Related changes
Get daily alerts for USPTO Patent Applications - Biotech (C12N)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Biotech (C12N) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.